{
    "clinical_study": {
        "@rank": "147943", 
        "arm_group": [
            {
                "arm_group_label": "Cohort 1", 
                "arm_group_type": "Experimental", 
                "description": "Mesenchymal Precursor Cells (MPCs) -  Dose 1 or Placebo"
            }, 
            {
                "arm_group_label": "Cohort 2", 
                "arm_group_type": "Experimental", 
                "description": "Mesenchymal Precursor Cells (MPCs) - Dose 2 or Placebo"
            }
        ], 
        "brief_summary": {
            "textblock": "The study investigates the safety, tolerability and efficacy of a single intravenous\n      infusion of two doses of mesenchymal precursor cells versus placebo in subjects with\n      diabetic nephropathy and type 2 diabetes."
        }, 
        "brief_title": "Safety and Efficacy of Mesenchymal Precursor Cells in Diabetic Nephropathy", 
        "completion_date": {
            "#text": "September 2015", 
            "@type": "Anticipated"
        }, 
        "condition": [
            "Diabetic Nephropathy", 
            "Type 2 Diabetes"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Diabetes Mellitus", 
                "Diabetes Mellitus, Type 2", 
                "Diabetic Nephropathies", 
                "Kidney Diseases"
            ]
        }, 
        "detailed_description": {
            "textblock": "This study is taking place in Melbourne, Australia."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Men and women who are  \u2265 50 and \u2264 85 years old\n\n          -  Subjects diagnosed with type 2 diabetes at least 2 years prior to Screening\n\n          -  Subjects with diabetic nephropathy and CKD stage 3b-4\n\n          -  Albumin-to-creatinine ratio (ACR) from a spot urine sample >30 and < 3000 mg/g  at\n             Screening\n\n          -  Subjects must be receiving standard of care treatment for their diabetic nephropathy\n             with an angiotensin converting enzyme inhibitor (ACEi) and/or an angiotensin II\n             receptor blocker (ARB) for at least 12 weeks prior to Screening.\n\n          -  HbA1c  < 10.0% at Screening\n\n        Exclusion Criteria:\n\n          -  Prior participation in any stem cell study\n\n          -  Women of childbearing potential\n\n          -  Potentially unreliable subjects and those judged by the Investigator to be unsuitable\n             for the study\n\n          -  History of active substance abuse  (including alcohol) within the past 2 years.\n             Current alcohol abuse is defined as daily consumption of  >3 alcoholic beverages\n             (i.e. > 21 alcoholic beverages per week)\n\n          -  Body weight >150 kg\n\n          -  Subjects with non-diabetic renal disease e.g. known polycystic kidney disease\n\n          -  Subjects with a history of a renal transplant or who have had prior dialysis within 3\n             months of Screening and/or have not maintained a stable level of kidney function\n             within 3 months of Screening\n\n          -  Current or history within 6 months of Screening of NYHA Class III or IV heart failure\n\n          -  Myocardial infarction or stroke within 6 months prior to Screening\n\n          -  Any concurrent medical condition/disorder or clinically symptomatic cardiovascular,\n             gastrointestinal, hematological, pulmonary,  acute or chronic infectious disease,\n             active retinal disease or other disorder which in the Investigator's opinion would\n             interfere with the subjects ability to complete the trial, would require\n             administration of treatment that could affect the interpretation of the efficacy and\n             safety variables or would preclude safe involvement in the study"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "85 Years", 
            "minimum_age": "50 Years"
        }, 
        "enrollment": {
            "#text": "30", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "April 23, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01843387", 
            "org_study_id": "MSB-DN001"
        }, 
        "intervention": [
            {
                "arm_group_label": "Cohort 1", 
                "description": "Single Intravenous Infusion of MPCs Dose 1 or Placebo", 
                "intervention_name": "Mesenchymal Precursor Cells (MPCs)", 
                "intervention_type": "Biological"
            }, 
            {
                "arm_group_label": "Cohort 2", 
                "description": "Single Intravenous Infusion of MPCs Dose 2 or Placebo", 
                "intervention_name": "Mesenchymal Precursor Cells (MPCs)", 
                "intervention_type": "Biological"
            }
        ], 
        "is_fda_regulated": "No", 
        "keyword": [
            "Diabetic nephropathy", 
            "Chronic kidney disease", 
            "Metabolic disease", 
            "Diabetes mellitus, type 2"
        ], 
        "lastchanged_date": "January 7, 2014", 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Clayton", 
                        "country": "Australia"
                    }, 
                    "name": "Monash Universtiy"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Melbourne", 
                        "country": "Australia"
                    }, 
                    "name": "Melbourne Renal Research Group"
                }, 
                "status": "Recruiting"
            }
        ], 
        "location_countries": {
            "country": "Australia"
        }, 
        "number_of_arms": "2", 
        "official_title": "A Randomized, Controlled, Dose-Escalation Pilot Study to Assess the Safety and Efficacy of a Single Intravenous Infusion of Allogeneic Mesenchymal Precursor Cells (MPCs) in Subjects With Diabetic Nephropathy and Type 2 Diabetes", 
        "overall_contact": {
            "email": "karen.segal@mesoblast.com", 
            "last_name": "K Segal, PhD", 
            "phone": "212-880-2060"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "Australia: Human Research Ethics Committee", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 1/Phase 2", 
        "primary_completion_date": {
            "#text": "September 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "Outcomes include the following safety parameters:\nNumber of and percent of subject with adverse events and serious adverse events\nClinically significant values and shifts from baseline in vital signs, physical examinations and electrocardiograms\nClinical laboratory tests (hematology, chemistry and urinalysis, flow cytometry with Class I and Class II PRA % with specificity)", 
            "measure": "The primary objective of the study is to assess the safety and tolerability of MPC therapy", 
            "safety_issue": "Yes", 
            "time_frame": "60 Weeks"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01843387"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": {
            "description": "Outcomes include changes from baseline at 12 weeks in the following parameters:\nRenal function (glomerular filtration rate, renal blood flow)\nSerum creatinine\nUrinary albumin and protein excretion\nGlycemic control\nBiomarkers", 
            "measure": "Exploratory assessment of the efficacy of MPC therapy", 
            "safety_issue": "No", 
            "time_frame": "12 Weeks"
        }, 
        "source": "Mesoblast, Ltd.", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Mesoblast, Ltd.", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "July 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "January 2014"
    }
}